NASDAQ · CLYM
Healthcare · Biotechnology
$14.57
Down-$0.49 (-3.25%)
Updated Aug 30, 2026, 1:11 PM
SID Score
5.8/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance
1M range · 0 trading sessions · Daily adjusted prices
CLYM does not have enough price history for the selected period.
Data unavailable
Market data is busy. Please try again shortly.
The latest Smart Investors Daily articles mentioning CLYM.
CLYM research
Company profile and research snapshot.
Climb Bio Inc is a clinical-stage biotechnology company developing therapeutics for patients with immune-mediated diseases. its product candidate, budoprutug, is an anti-CD19 monoclonal antibody that has demonstrated B-cell depletion and has the potential to treat a broad range of B-cell-mediated diseases.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Aug 24, 2026 | HC Wainwright & Co. | Buy | — |
| Aug 19, 2026 | Wedbush | Outperform | — |
| Aug 7, 2026 | Truist Securities | Buy | — |
| Jul 27, 2026 | Wedbush | Outperform | — |
| Jun 24, 2026 | HC Wainwright & Co. | Buy | — |
No generated briefing is available yet.
Finnhub · May 12, 2026
WELLESLEY HILLS, Mass., May 12, 2026 -- Climb Bio, Inc. , a clinical stage biotechnology company developing therapeutics for patients with immune-mediated diseases, today announced that members of...
Benzinga · May 12, 2026
HC Wainwright & Co. analyst Raghuram Selvaraju maintains Climb Bio (NASDAQ:CLYM) with a Buy and raises the price target from $15 to $20.
Benzinga · May 8, 2026
Wedbush analyst Laura Chico maintains Climb Bio (NASDAQ:CLYM) with a Outperform and raises the price target from $15 to $17.
Yahoo · May 7, 2026
Robust B-cell depletion observed with budoprutug subcutaneous formulation in healthy volunteers, supporting continued development CLYM116 modeling and initial Phase 1 safety data to be presented at ERA 2026 with initial Phase 1 PK/PD data expected mid-2026 Budoprutug pMN, ITP, and SLE clinical trials enrolling to plan; anticipate data from all ongoing trials in 2026 Secured $110 million private placement led by top-tier healthcare investors WELLESLEY HILLS, Mass., May 07, 2026 (GLOBE NEWSWIRE) -
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning CLYM.
